3:36 KEYNOTE-177: translating results for patients and clinicians 7:37 Dr. Nazik Hammad presents Keynote-177 (GI cancer) 2:22 KEYNOTE-177 0:44 KEYNOTE-177 and CheckMate 8HW: promising first-Line immunotherapy for MSI-H mCRC 6:57 KEYNOTE-177 discussion: chemo-immunotherapy, pseudoprogression & biomarkers 2:56 KEYNOTE-177: final PFS analysis of pembrolizumab in patients with MSI-H/dMMR mCRC 3:53 ASCO GI: updates in KEYNOTE-177, IMbrave150 & ClarIDHy 0:53 Dr. Chu on the Impact of the KEYNOTE-177 Trial in mCRC 6:00 ASCO 2020 | Keynote-177: Pembrolizumab versus Quimioterapia para cólon MSI-H 1:08 Dr. Ahn on the KEYNOTE-177 Trial in Newly Diagnosed MSI-H/dMMR mCRC 6:56 KEYNOTE-177 results: Pembrolizumab versus chemotherapy for patients with MSI-H/dMMR colorectal c... 1:04 Dr. Halfdanarson on the KEYNOTE-177 Trial in MSI-H/dMMR mCRC 5:35 Howard Hochster, MD, discusses the outcomes of the Keynote-177 study in metastatic CRC 3:44 KEYNOTE-177 & CheckMate 142: checkpoint blockade in MSI-H/dMMR CRC 8:40 Thierry Andre, ASCO20: Phase III KEYNOTE-177 Trial of Pembrolizumab in Metastatic Colorectal Cancer 3:22 Alan Venook, MD, on the Keynote-177 study investigating MSI High/mismatch repair deficient mCRC 1:08 Thierry Andre, MD, regarding the outcomes of the Keynote-177 study in metastatic colorectal cancer 1:35 Dr. Andre on the Rationale for the KEYNOTE-177 Trial in mCRC